Teva Historical Income Statement
TEVA Stock | USD 13.98 0.10 0.71% |
Historical analysis of Teva Pharma income statement accounts such as Other Operating Expenses of 7.6 B, Operating Income of 732.2 M, EBIT of 411.4 M or Ebitda of 411.4 M can show how well Teva Pharma Industries performed in making a profits. Evaluating Teva Pharma income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Teva Pharma's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Teva Pharma Industries latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Teva Pharma Industries is a good buy for the upcoming year.
Teva |
About Teva Income Statement Analysis
Teva Pharma Industries Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Teva Pharma shareholders. The income statement also shows Teva investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Teva Pharma Income Statement Chart
Teva Pharma Industries Income Statement is one of the three primary financial statements used for reporting Teva's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Teva Pharma Industries revenue and expense. Teva Pharma Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Teva Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 732.2 M, whereas Depreciation And Amortization is forecasted to decline to about 667.3 M. Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Teva Pharma Industries. It is also known as Teva Pharma overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Net Income Applicable To Common Shares
The net income that remains after preferred dividends have been deducted, available to common shareholders.Interest Income
Income earned from the investment of cash or from lending money to others, including interest from bank accounts, bonds, or other interest-bearing investments.Most accounts from Teva Pharma's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Teva Pharma Industries current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. At present, Teva Pharma's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Operating Income is expected to grow to about 732.2 M, whereas Depreciation And Amortization is forecasted to decline to about 667.3 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 7.6B | 7.0B | 7.6B | 4.8B | Total Revenue | 15.9B | 14.9B | 15.8B | 9.5B |
Teva Pharma income statement Correlations
Click cells to compare fundamentals
Teva Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Teva Pharma income statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Depreciation And Amortization | 1.8B | 416M | 1.6B | 1.3B | 1.2B | 667.3M | |
Interest Expense | 822M | 963M | 1.1B | 966M | 1.0B | 1.1B | |
Total Revenue | 16.9B | 16.7B | 15.9B | 14.9B | 15.8B | 9.5B | |
Gross Profit | 7.5B | 7.7B | 7.6B | 7.0B | 7.6B | 4.8B | |
Other Operating Expenses | 14.2B | 13.6B | 12.8B | 12.2B | 12.7B | 7.6B | |
Operating Income | (1.6B) | 2.8B | 3.1B | 3.2B | 433M | 732.2M | |
Ebit | 1.3B | 2.8B | 3.1B | 3.2B | 433M | 411.4M | |
Ebitda | 3.2B | 4.6B | 4.5B | 4.1B | 433M | 411.4M | |
Cost Of Revenue | 9.4B | 8.9B | 8.3B | 8.0B | 8.2B | 4.7B | |
Total Operating Expenses | 4.8B | 4.7B | 4.5B | 4.3B | 4.5B | 2.9B | |
Income Before Tax | (1.3B) | (4.4B) | 658M | (3.1B) | (624M) | (592.8M) | |
Total Other Income Expense Net | (4.1B) | (7.5B) | (2.5B) | (5.9B) | (1.1B) | (1.1B) | |
Net Income | (999M) | (4.0B) | 417M | (2.4B) | (559M) | (531.1M) | |
Income Tax Expense | (278M) | (168M) | 211M | (638M) | (65M) | (61.8M) | |
Research Development | 1.0B | 997M | 967M | 838M | 953M | 809.2M | |
Selling General Administrative | 1.2B | 1.2B | 1.1B | 1.2B | 1.2B | 1.2B | |
Net Income Applicable To Common Shares | (999M) | (4.0B) | 417M | (2.4B) | (2.1B) | (2.0B) | |
Minority Interest | (2M) | (109M) | 39M | 53M | 56M | 74.7M | |
Selling And Marketing Expenses | 2.6B | 2.5B | 2.4B | 2.3B | 2.3B | 3.2B | |
Net Income From Continuing Ops | (987M) | (4.2B) | 447M | (2.4B) | (615M) | (645.8M) | |
Tax Provision | (278M) | (168M) | 211M | (638M) | (7M) | (7.4M) | |
Net Interest Income | (877M) | (963M) | (962M) | (966M) | (1.1B) | (1.1B) | |
Reconciled Depreciation | 1.7B | 1.6B | 1.3B | 1.3B | 1.2B | 1.3B | |
Non Operating Income Net Other | (1.0B) | (835M) | (696M) | (1.0B) | (1.2B) | (1.3B) |
Currently Active Assets on Macroaxis
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Teva Pharma Industries. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Transaction History View history of all your transactions and understand their impact on performance | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.4 | Earnings Share (0.50) | Revenue Per Share 14.161 | Quarterly Revenue Growth 0.148 | Return On Assets 0.0454 |
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.